Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways

Curcumin [(1E,6E) ‑1,7‑bis(4‑hydroxy‑3‑methoxyphenyl) hepta‑1,6‑diene‑3,5‑ dione] is a natural polyphenol derived from the rhizome of the turmeric plant  . Accumulated evidences have presented curcumin's function in terms of anti-inflammatory, antioxidant properties, and especially anti-tumor a...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 660712
Main Authors Wang, Haijun, Zhang, Ke, Liu, Jia, Yang, Jie, Tian, Yidan, Yang, Chen, Li, Yushan, Shao, Minglong, Su, Wei, Song, Na
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 12.04.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Curcumin [(1E,6E) ‑1,7‑bis(4‑hydroxy‑3‑methoxyphenyl) hepta‑1,6‑diene‑3,5‑ dione] is a natural polyphenol derived from the rhizome of the turmeric plant  . Accumulated evidences have presented curcumin's function in terms of anti-inflammatory, antioxidant properties, and especially anti-tumor activities. Studies demonstrated that curcumin could exert anti-tumor activity multiple biological signaling pathways, such as PI3K/Akt, JAK/STAT, MAPK, Wnt/β-catenin, p53, NF-ĸB and apoptosis related signaling pathways. Moreover, Curcumin can inhibit tumor proliferation, angiogenesis, epithelial-mesenchymal transition (EMT), invasion and metastasis by regulating tumor related non-coding RNA (ncRNA) expression. In this review, we summarized the roles of curcumin in regulating signaling pathways and ncRNAs in different kinds of cancers. We also discussed the regulatory effect of curcumin through inhibiting carcinogenic miRNA and up regulating tumor suppressive miRNA. Furthermore, we aim to illustrate the cross regulatory relationship between ncRNA and signaling pathways, further to get a better understanding of the anti-tumor mechanism of curcumin, thus lay a theoretical foundation for the clinical application of curcumin in the future.
Bibliography:This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Edited by: Yue Hou, Northeastern University, China
Reviewed by: Jun Zhang, The University of Texas Health Science Center at San Antonio, United States; Feilin Liu, Mayo Clinic Florida, United States
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.660712